Johnson & Johnson vs Pfizer Inc., two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Johnson & Johnson is a diversified healthcare conglomerate, pharma plus medtech, running 66.3% gross margins; Pfizer is the purer drug company, and its current numbers are thinner, an 11.8% net margin to J&J's 21.8%. The market has separated them hard: 29.3 times earnings at $618.7B against 19.1 times at $143.6B. J&J earns 25.9% on equity to Pfizer's 8.3%. Pfizer's 6.9% dividend is doing a different job than J&J's 2%: it is the part of the return the market is most sure of.
Comparison updated 2026-07-19.
| Metric | JNJ | PFE |
|---|---|---|
| Price | $256.46 | $25.03 |
| Market cap | $625.8B | $143.4B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | -2.9% |
| P/E | 29.8 | 19.1 |
| P/B | 7.36 | 1.59 |
| P/S | 6.39 | 2.27 |
| EV/EBITDA | 326.4 | 31.3 |
| Revenue growth | +8.1% | +2.1% |
| Gross margin | 68.2% | — |
| Net margin | 21.5% | 11.8% |
| Return on equity | 24.8% | 8.3% |
| Return on assets | 10.5% | 3.6% |
| FCF yield | 3.5% | 6.6% |
| Dividend yield | 2.0% | 6.9% |
| Debt / equity | 0.58 | 0.71 |
| Current ratio | 1.09 | 1.25 |
| Altman Z (solvency) | 4.95 | 1.88 |
| Piotroski F (quality) | 8 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.